Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Hydromorphone vs SR Oxycodone in Chronic Non-malignant Pain
NCT00261495Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2006
- Primary completion
- Apr 2008
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of hydromorphone in Chronic non-cancer pain (CNCP) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change From Baseline in Brief Pain Inventory (BPI) Questionnaire Item 6 'Pain Right Now' Score at 24 weeks and Equi-analgesic Dosage of OROS Hydromorphone Once-daily and SR Oxycodone Twice-daily at 24 weeks. Started Mar 2006; status: completed.
02
Drugs
hydromorphone
03
Conditions
Chronic non-cancer pain (CNCP)
Beyond the preview
Go deeper on NCT00261495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261495.